Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

symbols : EBS    crawled date : 2021 - 01 - 25    save search

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
Published: 2021-01-25 (Crawled : 18:00) - biospace.com/
EBS | $1.955 2.9% 350K twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.0% C: -0.7%
HGEN | $0.0361 -61.5% 120M twitter stocktwits trandingview |
Health Technology
| | O: 0.71% H: 1.32% C: -2.74%

covid contract phase 3 merge lenzilumab
Gainers vs Losers
72% 28%

Top 10 Gainers
AGBA | $1.05 162.5% 100M twitter stocktwits trandingview |
Finance

ISPC | $0.4621 116.95% 15M twitter stocktwits trandingview |
Professional, Scientific, and T...

INVO | $1.515 99.34% 4.3M twitter stocktwits trandingview |
Health Technology

BPTH | $5.62 73.46% 75M twitter stocktwits trandingview |
Health Technology

TIRX | $0.8231 69.78% 54M twitter stocktwits trandingview |

SINT | $0.0519 39.14% 350M twitter stocktwits trandingview |
Health Technology

XPON | $2.63 36.27% 8.4M twitter stocktwits trandingview |

VTNR S | $1.26 28.68% 9.1M twitter stocktwits trandingview |
Industrial Services

SWVL | $9.64 27.35% 200K twitter stocktwits trandingview |
n/a

DFLI A | $0.7726 25.52% 4.3M twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.